Prenatal DiagnosisNCT07515976
Mapping of Genomic Structural Variations in Major Birth Defects
An observational study of Prenatal Diagnosis, run by Peking Union Medical College Hospital.
Trial summary
In the context of intricate cases with ambiguous prenatal genetic diagnoses, this project intends to carry out long - read DNA sequencing data analysis on birth defect cases and family samples. Read more about this study
- Who is it for?
- Ages 20 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Prenatal Diagnosis
- What is being tested?
- Long - read DNA sequencing
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 May 2026to 30 Nov 2027
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Pregnant patients at Peking Union Medical College Hospital
Who may be able to join
- Single pregnancy with ultrasound findings of fetal structural abnormalities
- Negative results for prenatal WES, karyotyping, CMA, etc.
- Only one heterozygous pathogenic variant is detected in a suspected recessive genetic disorder, with no second suspected pathogenic variant identified.
Who cannot join
- Twin/multiple pregnancy
- No interventional prenatal diagnosis performed
- Refusing further testing
About this study
In the context of intricate cases with ambiguous prenatal genetic diagnoses, this project intends to carry out long - read DNA sequencing data analysis on birth defect cases and family samples. The emphasis lies on the extraction and identification of individual - specific genomic characteristics, as well as the development of detection algorithms for all categories of structural variations (SV), including complex SV. It will establish a pan - genomic reference map specific to the Chinese population to facilitate the identification of pathogenic SV in birth defect cases and family samples of the Chinese population, and delineate the detailed SV spectrum of major birth defects in the Chinese population. Additionally, the project will conduct in - depth analyses of the genetic and pathogenic roles of different types of SV in birth defects, offering a theoretical foundation for promoting the early warning, intervention, and prevention of major birth defects in China.
Read the detailed description
Based on the long - read DNA sequencing of cases carried out in Project Topics 1 and 3, this study incorporates case and control samples, along with their long - read sequencing data. The PacBio Revio platform was chosen for long - read DNA sequencing, and standard whole - genome long - read sequencing analysis was performed on 50 cases. Building on the first - phase China population pan - genome reference map that had already been constructed, 50 representative control samples were added for long - read sequencing to construct a new China population pan - genome reference map. The specific details are as follows:
- Extraction of structural variation (SV) characteristics and encoding of birth defect case genomes, and establishment of an SV detection method based on feature encoding. Sequence imaging was utilized to eliminate background repetitive information from site alignment signals, thereby facilitating SV detection in complex genomic regions. An "image compression" encoding method was explored, using a "stacking" approach to characterize abnormal sequence features between birth defect cases and parental controls or population controls within a single image. Based on whole - genome alignment results, the genomic regions containing abnormal sequences in birth defect cases were identified. A local breakpoint - sensitive realignment method based on collinear segments was established to extract SV fragment features carried in sequencing reads between birth defect cases and parental controls or population controls. The study focused on researching an isomorphic convolutional neural network framework capable of simultaneous target segmentation and classification, achieving both in SV detection.
- Construction of a China population pan - genome reference map based on long - read DNA sequencing data. Leveraging third - generation whole - genome sequencing technology, DNA samples from multiple ethnic groups in China were sequenced, and the visualization of pan - genome assembly was realized. Ethnic - specific reference genomes were constructed to form a pan - genome graph, integrating DNA sequences from different populations. Genetic variants or sequences with differences were regarded as nodes, and adjacent sequences were connected by edges, thereby identifying core and specific gene sequences in the China population. This endeavor aims to establish a high - quality pan - genome reference map exclusive to the Chinese population, with a focus on studying whole - genome structural variation (SV) maps to support the precise analysis of rare or novel SVs in birth defects.
- Mapping of the fine SV map of major birth defects in the China population. SV detection is carried out through two approaches: the linear genome approach and the pan - genome approach. The linear genome approach employs conventional linear detection methods to identify genetic variants. The pan - genome approach involves constructing a genome map using de novo assembled genomes, the universal human reference genome (GRCh38), and genetic variant and birth defect case samples discovered in the China population. These two approaches mutually validate and complement each other, integrating the obtained SV results. Thresholds are set based on criteria such as the location of variants and sequence similarity, and redundant results are removed.
- Conditions
- Prenatal Diagnosis
- Being tested
- Long - read DNA sequencing
- Keywords
- structural variations, long - read DNA sequencing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Long - read DNA sequencingDiagnostic test
The sample DNA was sequenced using long - read DNA sequencing technology.
| Study group | Role | What they receive |
|---|---|---|
| Cases | * Single pregnancy with ultrasound findings of fetal structural abnormalities
* Negative results for prenatal WES, karyotyping, CMA, etc.
* Alternatively, only one heterozygous pathogenic variant is detected in a suspected recessive genetic disorder, with no second suspected pathogenic variant identified. Receives: Diagnostic Test: Long - read DNA sequencing |
What is being measured
The primary outcome is the main question the study is designed to answer.
Complex genomic structural aberrations
The test detected that the subject carried complex genomic structural aberrations.
Measured: When the test is completed,up to 6 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2026
- Study start1 May 2026 (estimated)
- Primary completion31 May 2027 (estimated)
- Study completion30 Nov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prenatal DiagnosisStudies of the same condition, open and under way.
- More trials run by Peking Union Medical College HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Peking Union Medical College Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07515976
- Sponsor's protocol ID
- K7861
- Status last verified
- Feb 2026
- First submitted
- 10 Mar 2026
- Last updated
- 7 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: IPD will not be shared publicly due to ethical and legal restrictions. The data contain sensitive genetic information and the informed consent does not include permission for public data archiving.
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Mapping of Genomic Structural Variations in Major Birth Defects
- ClinicalTrials.gov ID
- NCT07515976
- Acronym / sponsor ID
- K7861
- Conditions
- Prenatal Diagnosis
- Keywords
- structural variations, long - read DNA sequencing
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Peking Union Medical College HospitalUniversity, hospital or other
- Study start
- 1 May 2026 (estimated)
- Primary completion
- 31 May 2027 (estimated)
- Study completion
- 30 Nov 2027 (estimated)
- First posted
- 7 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In the context of intricate cases with ambiguous prenatal genetic diagnoses, this project intends to carry out long - read DNA sequencing data analysis on birth defect cases and family samples. The emphasis lies on the extraction and identification of individual - specific genomic characteristics, as well as the development of detection algorithms for all categories of structural variations (SV), including complex SV. It will establish a pan - genomic reference map specific to the Chinese population to facilitate the identification of pathogenic SV in birth defect cases and family samples of the Chinese population, and delineate the detailed SV spectrum of major birth defects in the Chinese population. Additionally, the project will conduct in - depth analyses of the genetic and pathogenic roles of different types of SV in birth defects, offering a theoretical foundation for promoting the early warning, intervention, and prevention of major birth defects in China.
Detailed description
Based on the long - read DNA sequencing of cases carried out in Project Topics 1 and 3, this study incorporates case and control samples, along with their long - read sequencing data. The PacBio Revio platform was chosen for long - read DNA sequencing, and standard whole - genome long - read sequencing analysis was performed on 50 cases. Building on the first - phase China population pan - genome reference map that had already been constructed, 50 representative control samples were added for long - read sequencing to construct a new China population pan - genome reference map. The specific details are as follows:
- Extraction of structural variation (SV) characteristics and encoding of birth defect case genomes, and establishment of an SV detection method based on feature encoding. Sequence imaging was utilized to eliminate background repetitive information from site alignment signals, thereby facilitating SV detection in complex genomic regions. An "image compression" encoding method was explored, using a "stacking" approach to characterize abnormal sequence features between birth defect cases and parental controls or population controls within a single image. Based on whole - genome alignment results, the genomic regions containing abnormal sequences in birth defect cases were identified. A local breakpoint - sensitive realignment method based on collinear segments was established to extract SV fragment features carried in sequencing reads between birth defect cases and parental controls or population controls. The study focused on researching an isomorphic convolutional neural network framework capable of simultaneous target segmentation and classification, achieving both in SV detection.
- Construction of a China population pan - genome reference map based on long - read DNA sequencing data. Leveraging third - generation whole - genome sequencing technology, DNA samples from multiple ethnic groups in China were sequenced, and the visualization of pan - genome assembly was realized. Ethnic - specific reference genomes were constructed to form a pan - genome graph, integrating DNA sequences from different populations. Genetic variants or sequences with differences were regarded as nodes, and adjacent sequences were connected by edges, thereby identifying core and specific gene sequences in the China population. This endeavor aims to establish a high - quality pan - genome reference map exclusive to the Chinese population, with a focus on studying whole - genome structural variation (SV) maps to support the precise analysis of rare or novel SVs in birth defects.
- Mapping of the fine SV map of major birth defects in the China population. SV detection is carried out through two approaches: the linear genome approach and the pan - genome approach. The linear genome approach employs conventional linear detection methods to identify genetic variants. The pan - genome approach involves constructing a genome map using de novo assembled genomes, the universal human reference genome (GRCh38), and genetic variant and birth defect case samples discovered in the China population. These two approaches mutually validate and complement each other, integrating the obtained SV results. Thresholds are set based on criteria such as the location of variants and sequence similarity, and redundant results are removed.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Cases | – | Diagnostic Test: Long - read DNA sequencing* Single pregnancy with ultrasound findings of fetal structural abnormalities * Negative results for prenatal WES, karyotyping, CMA, etc. * Alternatively, only one heterozygous pathogenic variant is detected in a suspected recessive genetic disorder, with no second suspected pathogenic variant identified. |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Pregnant patients at Peking Union Medical College Hospital
Key inclusion criteria (3 listed)
- Single pregnancy with ultrasound findings of fetal structural abnormalities
- Negative results for prenatal WES, karyotyping, CMA, etc.
- Only one heterozygous pathogenic variant is detected in a suspected recessive genetic disorder, with no second suspected pathogenic variant identified.
Key exclusion criteria (3 listed)
- Twin/multiple pregnancy
- No interventional prenatal diagnosis performed
- Refusing further testing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Long - read DNA sequencingThe sample DNA was sequenced using long - read DNA sequencing technology. | Diagnostic test | Cases |
Primary outcome
Complex genomic structural aberrations
Time frame: When the test is completed,up to 6 weeks
The test detected that the subject carried complex genomic structural aberrations.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2026.
- Individual participant dataSharing planned: No. IPD will not be shared publicly due to ethical and legal restrictions. The data contain sensitive genetic information and the informed consent does not include permission for public data archiving.
Related trials for Prenatal Diagnosis
Not yet recruitingPhase 2
CAffeine Use in Prolonged Oxygen Use in meConium aspIration Syndrome in Neonatal Outcomes (CAPUCINO)
Meconium Aspiration Syndrome
Recruiting
Amnioinfusion for Chorioamnionitis: Targeting Neonatal Brain Injury Biomarkers
Chorioamnionitis Affecting Fetus or Newborn, Amnioinfusion
Not yet recruiting
Inflammatory Pathways Modulated by Prenatal Mindfulness: A Route to Improve Maternal Child Emotional Well Being and Whole Person Health
Inflammation, Depression Disorder
Not yet recruiting
Usability Evaluation of Gen AI-based Nutrition Chatbot for Pregnant Women
Diabetes, Gestational, Pre-eclampsia
Recruiting
Effects Of Core Canister Training in Pregnant Women With History of Gestational Diabetes Mellitus
Antenatal Care Model, Gestatiaonl Diabetes Mellitus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Prenatal Diagnosis, run by Peking Union Medical College Hospital.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 7 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Complex genomic structural aberrations (time frame: When the test is completed,up to 6 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2026.